Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
The approval marks a major milestone in the global fight against antimicrobial resistance
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
The conference highlighted research suggesting that deuterium levels may influence key biological processes
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Subscribe To Our Newsletter & Stay Updated
